These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34544612)

  • 1. Corrigendum to "Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance" [Crit. Rev. Oncol./Hematol. 164 (2021) 1-11/103424].
    Muraro E; Fanetti G; Lupato V; Giacomarra V; Steffan A; Gobitti C; Vaccher E; Franchin G
    Crit Rev Oncol Hematol; 2021 Oct; 166():103479. PubMed ID: 34544612
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to "The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity" [Crit. Rev. Oncol./Hematol. 116 (2017) 82-88].
    Bossi P; Cossu Rocca M; Corvò R; Depenni R; Guardamagna V; Marinangeli F; Miccichè F; Trippa F
    Crit Rev Oncol Hematol; 2017 Nov; 119():29. PubMed ID: 29065982
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrigendum to "Endoscopic resection with adjuvant chemo-radiotherapy for superficial esophageal squamous cell carcinoma: A critical review" [Crit. Rev. Oncol./Hematol. 124, April (2018), 61-65].
    Kam TY; Kountouri M; Roth A; Frossard JL; Huber O; Mönig S; Zilli T
    Crit Rev Oncol Hematol; 2018 Aug; 128():139. PubMed ID: 29731124
    [No Abstract]   [Full Text] [Related]  

  • 4. Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance.
    Muraro E; Fanetti G; Lupato V; Giacomarra V; Steffan A; Gobitti C; Vaccher E; Franchin G
    Crit Rev Oncol Hematol; 2021 Aug; 164():103424. PubMed ID: 34245856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum to "Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis" [Crit. Rev. Oncol./Hematol. 201 (2024) 104416].
    Veas Rodríguez J; Prieto A; Vilaprinyo E; Bonet M; Diez M; Salud A; Montal R
    Crit Rev Oncol Hematol; 2024 Oct; 202():104466. PubMed ID: 39127520
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Bartholin gland cancer" [Crit. Rev. Oncol./Hematol. 117 (September) (2017) 1-11].
    Di Donato V; Casorelli A; Bardhi E; Vena F; Marchetti C; Muzii L; Panici PB
    Crit Rev Oncol Hematol; 2019 Jan; 133():84. PubMed ID: 30661661
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Advances in laparoscopic surgery for cervical cancer" [Crit. Rev. Oncol. Hematol. 143 (August) (2019) 76-80].
    Bogani G; Leone Roberti Maggiore U; Rossetti D; Ditto A; Martinelli F; Chiappa V; Ferla S; Indini A; Sabatucci I; Lorusso D; Raspagliesi F
    Crit Rev Oncol Hematol; 2020 Jan; 145():102833. PubMed ID: 31783292
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Evaluation and management of skeletal disease in cancer care" [Crit. Rev. Oncol./Hematol. 120 (December 2017) 217-226].
    Kommalapati A; Tella SH; Esquivel MA; Correa R
    Crit Rev Oncol Hematol; 2018 Apr; 124():73. PubMed ID: 29496392
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Imaging predictors of treatment outcomes in rectal cancer: An overview" [Crit. Rev. Oncol./Hematol. 129, (September) (2018), 153-162].
    ShreeMahadevan L; Zhong J; Venkatesulu B; Kaur H; Bhide S; Minsky B; Chu W; Intven M; van der Heide UA; Triest B; Krishnan S; Hall W
    Crit Rev Oncol Hematol; 2019 Feb; 134():71. PubMed ID: 30771876
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156].
    Addeo A; Tabbò F; Robinson T; Buffoni L; Novello S
    Crit Rev Oncol Hematol; 2019 Jul; 139():158. PubMed ID: 30396775
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer" [Crit. Rev. Oncol. Hematol. 137, May (2019) 57-83].
    Gonzalez-Avila G; Sommer B; Mendoza-Posada DA; Ramos C; Garcia-Hernandez AA; Falfan-Valencia R
    Crit Rev Oncol Hematol; 2019 Jun; 138():172. PubMed ID: 31092373
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy" [Crit. Rev. Oncol./Hematol. 128 (August) (2018) 110-117].
    Zhao B; Zhao H; Zhao J
    Crit Rev Oncol Hematol; 2019 Mar; 135():20. PubMed ID: 30819442
    [No Abstract]   [Full Text] [Related]  

  • 13. Erratum to "Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?" [Crit. Rev. Oncol. Hematol., 119 (November) (2017) 40-49].
    van der Weijst L; Surmont V; Schrauwen W; Lievens Y
    Crit Rev Oncol Hematol; 2017 Dec; 120():234-236. PubMed ID: 29055771
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "The cyclin-dependent kinases pathway as a target for prostate cancer treatment: Rationale and future perspectives" [Crit. Rev. Oncol. Hematol. 157 (January) (2021) 103199].
    Brighi N; Conteduca V; Lolli C; Gurioli G; Schepisi G; Palleschi M; Mariotti M; Casadei C; De Giorgi U
    Crit Rev Oncol Hematol; 2021 Aug; 164():103401. PubMed ID: 34275720
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "The emerging HER2 landscape in Colorectal Cancer: The key to unveil the future treatment algorithm?" [Crit. Rev. Oncol./Hematol. 204 (2024) 104515].
    Antonuzzo L
    Crit Rev Oncol Hematol; 2024 Oct; ():104530. PubMed ID: 39414526
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978].
    Rolfo C; Cardona AF; Cristofanilli M; Paz-Ares L; Diaz Mochon JJ; Duran I; Raez LE; Russo A; Lorente JA; Malapelle U; Gil-Bazo I; Jantus-Lewintre E; Pauwels P; Mok T; Serrano MJ;
    Crit Rev Oncol Hematol; 2020 Oct; 154():103058. PubMed ID: 32823147
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?" [Crit. Rev. Oncol. Hematol. 138 (June) (2019), 87-103].
    Frega S; Dal Maso A; Ferro A; Bonanno L; Conte PF; Pasello G
    Crit Rev Oncol Hematol; 2019 Aug; 140():73. PubMed ID: 31176852
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to ""Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer" [Crit. Rev. Oncol. Hematol. 133 (January) (2019) 17-24].
    Lombardi P; Silvestri S; Marino D; Santarelli M; Campra D; De Paolis P; Aglietta M; Leone F;
    Crit Rev Oncol Hematol; 2020 Apr; 148():102867. PubMed ID: 32062312
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives" [Crit. Rev. Oncol./Hematol. 181 (2023) 103900].
    Sirico M; Virga A; Conte B; Urbini M; Ulivi P; Gianni C; Merloni F; Palleschi M; Gasperoni M; Curcio A; Saha D; Buono G; Muñoz M; De Giorgi U; Schettini F
    Crit Rev Oncol Hematol; 2024 Aug; 200():104308. PubMed ID: 38876959
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to: The hematopoietic microenvironment of the fetal liver and transient abnormal myelopoiesis associated with Down syndrome: A review [Crit. Rev. Oncol. / Hematol., 199 (2024) 104382].
    Miyauchi J
    Crit Rev Oncol Hematol; 2024 Aug; 200():104409. PubMed ID: 38880662
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.